Heart health diagnostics firm GENinCode (LON: GENI) has received California state licensing approval and CLIA certification for its laboratory in Irvine, California. That sparked a 135.5% leap in the share price to 18.25p. That is the highest the share price has been since June and stops the downward trend since flotation in 2021. The certification will allow processing of LipidinCode, which is set to be launched in the US first, and CardioinCode tests. There are plans to obtain FDA approval for CardioinCode. There should be enough cash in the bank to last until the end of 2023.
Oil and gas company Challenger Energy (LON: CEG) says Uruguay has awarded two more offshore blocks, including one to a consortium including Shell, which is adjacent to Challenger Energy’s AREA OFF-1 block. A farm-in partner will be sought and that will enable increased exploration spending. The shares are 10.8% ahead at 0.1025p.
In-video game advertising technology company Bidstack (LON: BIDS) says that it has invoiced Azerion Technology, but it has received a termination notice from the company. Bidstack says that there is no entitlement to end the agreement and it is claiming damages. Azerion Technology has been in dispute since October and this deal was underpinning forecasts. The share price slumped 27% to 2.025p.
Helium One Global (LON: HE1) will not be able to procure the Exalo drilling rig as it had expected because the current user has taken up a 12-month option on its operation. This will delay exploration drilling, which was due to start in the first quarter of 2023. At the end of last year, Helium One Global raised £9.9m at 5p a share to finance a single exploration well in the Tai prospect in the Rukwa Basin, Tanzania, which would help to prove up a working helium system. There are alternative rigs that could be secured, but this will mean drilling starting later in the year. The share price declined by 23.2% to 5.45p.
DeepMatter (LON: DMTR) has fallen 7.69% to 0.03p ahead of the cancellation of its AIM quotation on 5 January.
Optamer binders developer Aptamer Group (LON: APTA) has warned that delays in signing contracts mean that full year revenues will be below expectations. Interim revenues are likely to fall from £1.4m to £1m and Liberum has cut its full year forecast from £8m to £6m, which is still a 50% increase on last year. Net cash of around £2.2m is forecast for the end of June 2023, so Aptamer is financially secure. The share price fell by 6.86% to 47.5p. Trading in Allergy Therapeutics (LON: AGY), Kazera Global (LON: KZG), Star Phoenix (LON: STA), URU Metals (LON: URU), Ince Group (LON: INCE), Inspirit Energy (LON: INSP) and Goldplat (LON: GDP) has been
